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HRAS rare alleles have been associated with the increased
susceptibility to a variety of cancers. In the present study
we examined the hypothesis that HRAS rare alleles are a
risk factor for adult glioma in a population-based case-
control study of adult glioma in six San Francisco Bay
Area counties. We compared the prevalence of rare alleles
in the variable number of tandem repeats region of HRAS
in the germline DNA from 73 white adults who had
gliomas with that of 65 controls. Overall, the prevalence
of rare alleles in cases was not different from the preva-
lence of those in controls according to two denitions of
rare alleles. We found that 25 of 73 (34%) of cases versus
25 of 65 (38%) of controls had at least one allele that was
not 30, 46, 69, or 87 repeats; 4 of 73 (5%) of cases versus
6 of 65 (9%) of controls carried one or more alleles with
33, 39, 42, 53, 59, 63, 68, 105, or 114 repeats. The pro-
portion of rare alleles was somewhat higher among sub-
jects with anaplastic astrocytoma. Among women, cases
were less likely than controls to have HRAS rare alleles,
whereas among men, cases were slightly more likely to
have HRAS rare alleles, but none of these results
approach statistical signicance. Our data do not suggest
an excess of HRAS rare alleles among adult glioma cases.
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Oncology [serial online], Doc. 99-46, March 22, 2000.
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Cancer is thought to arise as the result of multiplemolecular genetic alterations within tumor cells.These genetic changes fall into two general
classes: inactivation of tumor suppressor genes that oper-
ate physiologically to restrain growth and activation of
proto-oncogenes whose activation can enhance tumor
activity. The human HRAS gene is a proto-oncogene
homologous to a family of ras viral oncogenes. Activa-
tion mutations of HRAS have been implicated in activat-
ing a signal transduction pathway that leads to neoplastic
transformation of normal cells (reviewed in Barbacid,
1987). In addition to the activation mutations found in
human cancer, specic alleles in the HRAS hypervariable
minisatellite loci have shown an association with
increased susceptibility to a variety of cancers, including
bladder, breast, colorectal, and lung cancers, as well as
leukemia and melanoma (Krontiris et al., 1993). This
minisatellite, located 1 kb downstream to the HRAS cod-
ing sequences, contains a region with VNTRs3 of a
28–base pair sequence (Capon et al., 1983). It has been
shown that this minisatellite region is capable of binding
members of rel/NF-kb transcription regulatory factors
(Trepicchio and Krontiris, 1992). The binding of the
VNTR region to transcription factors leads to modula-
tion of transcription activation/repression, and the effects
on transcription are allele specic (Green and Krontiris,
1993). One study reported a 3-fold excess of rare HRAS
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alleles in university research hospital patients with
diverse histologic types of brain tumors compared with
blood donor controls (Diedrich et al., 1988). Gliomas are
the most common type of primary brain tumor and
account for more than 40% of all benign and malignant
CNS neoplasms. The etiology of adult onset glioma is
unknown. Family history and several genes have been
implicated in molecular genetic studies. In the present
report, we used a polymerase chain reaction approach to
study the frequencies of HRAS rare alleles in persons
with glioma and controls from a case-control adult
glioma study.
Materials and Methods
The study population was a subgroup of 73 cases and
65 controls from the larger population-based case-con-
trol San Francisco Bay Area Adult Glioma Study (Wren-
sch et al., 1997). The parent study from which these
cases and controls were selected included 492 (82% of
603 eligible) incident adult glioma cases (aged >20
years) ascertained from January 8, 1991, to March 3,
1994, in 6 San Francisco Bay Area counties through the
rapid case ascertainment service of the Northern Cali-
fornia Cancer Center. Uniform neuropathology review
indicated 4 cases were not glioma, and specimens could
not be reviewed for 12 subjects. Thus, the parent study
included 476 cases. Controls (n = 462; 63% of those eli-
gible) were contacted through a random digit dialing
technique and were frequency-matched for gender and
age (within 5 years). We began collecting blood samples
partway through the study from 187 cases and 169 con-
trols. The subjects for allelotyping of the HRAS VNTR
region represented the rst available samples. DNA was
extracted from heparinized whole blood, and allelotyp-
ing of the HRAS VNTR region was done using a poly-
merase chain reaction approach as described previously
(Conway et al., 1996). Each sample was assigned 2
numbers corresponding to the numbers of 28–base pair
repeats between the anking primers. The assignment of
common versus rare alleles is determined by taking into
account the combinations of the frequency of alleles in
control populations, the size comparison with the previ-
ously dened common alleles (a1, a2, a3, and a4), and
the sequences of the 28–base pair repeats. The statistical
package SAS was used to summarize data and to com-
pute odds ratios and 95% CIs for rare versus common
alleles in cases versus controls (SAS, 1990). Odds ratios
and 95% CIs for comparing cases and controls for rare
versus common alleles were computed with the SAS
program PROC LOGISTIC. Both unadjusted odds
ratios and odds ratios adjusting for age and gender were
computed.
Results
Table 1 compares demographic characteristics and tumor
histology of cases in the study group with the overall par-
ent study population. Only whites, for both cases and
controls, were included in the HRAS VNTR study group
because distribution of HRAS allelotypes are highly eth-
nicity dependent (Weston et al., 1991), and 84% of peo-
ple in the Glioma Study are white. The HRAS VNTR
study group was younger than the overall study popula-
tion. This was true for cases (48.6 years old versus 54.2
years old) and controls (49.1 years old versus 53.7 years
old). The percentages of astrocytic gliomas in the parent
and this substudy were comparable (88% versus 84%).
However, the percentage of glioblastomas in the HRAS
VNTR study group was lower than in the parent study
population.
The distributions of specic HRAS VNTR alleles and
allelotypes in cases and controls are shown in Fig. 1. For
3 cases, molecular analysis was insufcient to resolve
both alleles, but indicated presence of at least one 30-
repeat allele. These 3 cases are not shown in Fig. 1. Over-
Table 1. The study group included in HRAS rare allele analysis compared with the overall study population of brain tumor cases and controls in
the San Francisco Bay Area Adult Glioma Study, 1991–1995
Total study population HRAS analyses population subset
Factor Cases (n = 476) Controls (n = 462) Cases (n = 73) Controls (n = 65)
Sex
Female (%) 43 45 40 43
Male (%) 57 55 60 57
Age (years) (mean ± SE) 54.2 ± 0.8 53.7 ± 0.8 48.6 ± 1.8 49.1 ± 1.9
Diagnosis by cell type: (%)a
All astrocytic tumors 417 (88) 61 (84)
Glioblastoma 281 (59) 32 (44)
Anaplastic astrocytoma 63 (13) 9 (12)
Astrocytoma 26 (6) 5 (7)
Oligoastrocytoma 47 (10) 15 (21)
Others 59 (12) 12 (16)
Race (white) (%) 84 86 100 100
The study group included whites only. 
aNumbers in parentheses are percent of total tumors.
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all, the prevalence of rare alleles in cases was not different
from the prevalence in controls using two denitions of
rare alleles. We found 25 of 73 (34%) of cases versus 25
of 65 (38%) of controls had at least one allele that was
not 30, 46, 69, or 87 repeats; 4 of 73 (5%) of cases ver-
sus 6 of 65 (9%) of controls carried one or more alleles of
33, 39, 42, 53, 59, 63, 68, 105, or 114 repeats (Table 2).
Table 2 shows the prevalence of the HRAS rare alleles
according to both denitions of rare by histologic type.
Odds ratios are 0.83 (95% CI = 0.4–1.7) for cases to
have at least one allele that was not 30, 46, 69, or 87
repeats and 0.57 (95% CI = 0.2–2.1) for cases to carry
one or more alleles of 33, 39, 42, 53, 59, 63, 68, 105, or
114 repeats. These odds ratios and CIs were altered only
slightly by adjustment for age and sex. These results do
not suggest an excess of HRAS rare alleles among adult
glioma cases. The proportion of rare alleles was some-
what higher among anaplastic astrocytic cases, but these
results are not statistically signicant. Table 3 shows that
in women cases were less likely than controls to have
HRAS rare alleles, while in men cases were slightly more
likely to have HRAS rare alleles.
Fig. 1. Percent distribution of HRAS variable number of tandem repeat (VNTR) alleles and allelotypes for adult glioma cases and controls. A. Per-
cent distribution of individual HRAS VNTR alleles. Numbers on the allele axis represent numbers of 28–base pair repeats in each allele. B. Percent
distribution of HRAS VNTR allelotypes. Numbers on the allelotype axis represent combined allelotypes for each subject. The rst two digits rep-
resent the number of repeats for the alleles with fewer repeats, and the last three digits represent the number of repeats for the alleles with more
repeats. Open bars and closed bars represent percentages of controls and cases with specic allelotypes, respectively.
Table 2. Frequencies of HRAS rare alleles in white brain tumor
patients and controls, stratied by tumor histopathology, in the San
Francisco Bay Area Adult Glioma Study, 1991–1995
HRAS allelotypes
Group No. rare (%)a No. rare (%)b
Control (n = 65) 25 (38) 6 (9)
All cases (n = 73) 25 (34) 4 (5)
Glioblastoma (n = 32) 12 (38) 2 (6)
Anaplastic astrocytoma (n = 9) 5 (55) 0 (0)
Astrocytoma (n = 5) 0 (0) 0 (0)
Oligodendroglioma (n = 7) 1 (14) 0 (0)
Oligoastrocytoma (n = 15) 5 (33) 2 (13)
Juvenile pilocytic astrocytoma (n = 3) 1 (33) 0 (0)
Ependymoma (n = 2) 1 (50) 0 (0)
aNumber and percentage of subjects who carry one or more rare alleles according to pre-
viously dened four common alleles by Southern blotting analyses. Alleles with 30, 46,
69, or 87 repeats corresponded to common alleles a1, a2, a3, and a4, respectively; all
else are rare alleles.
bNumber and percentage of subjects who carry one or more rare alleles according to Con-
way’s (K.C.) denition: 19, 33, 39, 42, 53, 59, 63, 68, 84, 105, and 114 repeats are rare;
all else are common. 
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Discussion
Although a wide variety of cancers have been investi-
gated for an association with rare HRAS alleles, results
have been inconclusive. Only one other study examined
the relationship between HRAS rare alleles and the
occurrence of brain tumors (Diedrich et al., 1988). This
study found higher incidence of rare hypervariable
HRAS alleles in intracranial tumor patients in compari-
son with healthy blood donors. We did not observe an
increased risk for adult glioma in individuals with HRAS
rare alleles. There are several differences in the studies
that might contribute to the different conclusions
reached. First, brain tumors included in the previous
study consisted of several heterogeneous histopathologic
types of cancers that were not included in our study (for
example, meningioma). Cytogenetic and molecular
genetic analyses of glioma indicate substantial genetic
heterogeneity even within and between histologic grades
of gliomas (von Deimling et al., 1995). Thus, different
groupings and classications of brain tumors may have
affected the study outcomes. Secondly, in the present
study, samples were drawn from glioma cases and con-
trols frequency-matched to cases by gender and age from
a population-based epidemiologic study, whereas the
other study compared a case series from an academic
hospital matched with healthy blood-donor controls. We
also took into consideration potential effects of ethnicity
on HRAS allelotypes by including only whites in this
allelotyping study. In addition, the molecular assays
employed in the two studies were different. Our
approach of using polymerase chain reaction–based
assays results in higher resolution of VNTR fragments
and thus increases the number of alleles detected for the
HRAS VNTR region. Finally, it should be noted that,
although our study was negative, it had 80% power to
detect odds ratios of 2.8 for rare allele denition one and
4.2 for rare allele denition two. The previous study indi-
cated an odds ratio of approximately 4 for gliomas, a
magnitude of risk our study should have been able to
detect. Thus, we were not able to conrm an association
of rare HRAS alleles with glioma risk.
Cases in this substudy of HRAS VNTR tended to be
younger and have lower grade tumors than all popula-
tion-based cases, because blood samples were not col-
lected until (at times up to 6 months) after the interview.
Thus, since younger patients and patients with lower
grades of brain tumors have better survival, they are
overrepresented in this sample. This difference was pri-
marily due to underrepresentation of the glioblastoma
group, the histologic type of glioma with the poorest sur-
vival. Although the percentage of glioblastoma cases in
the HRAS VNTR study group was lower than that of the
parent study population (44% versus 59%, Table 1), the
percentages of anaplastic astrocytoma cases were similar
between the HRAS VNTR study group and the parent
study population (12% versus 13%, Table 1). Another
factor that might contribute to nding no association of
HRAS VNTR rare alleles and glioblastoma is the fact
that glioblastomas are highly heterogeneous, genetically.
There is increasing evidence that glioblastoma consists of
several distinct entities with different genetic alterations
(Louis, 1997; Watanabe et al., 1996).
Because we found a somewhat positive association of
HRAS rare alleles with a small sample of subjects with
anaplastic astrocytoma, and because others have
reported overexpression of HRAS in high-grade astro-
cytoma tumors (Orian et al., 1992; Riccardi et al.,
1991), it may be worthwhile to follow-up with a study
to determine if the HRAS rare alleles are associated
with anaplastic astrocytoma in other populations.
Given that most high-grade astrocytomas that were
found in other studies to have elevated HRAS protein
expression were glioblastomas, and glioblastomas
themselves represent a highly heterogeneous group of
tumors, it might also be of interest to extend the studies
to subsets of glioblastoma that have a genetic profile
similar to anaplastic astrocytoma.
Table 3. Frequencies of HRAS rare alleles in white brain tumor patients and controls, stratied by sex, in the San Francisco Bay Area Adult 
Glioma Study, 1991–1995
Females Males
HRAS allelotypes Control (n = 28) Case (n = 29) Control (n = 37) Case (n = 44)
Rare, dened previouslya (%) 14 (50) 9 (31) 11 (30) 16 (36)
Rare, dened by Conwayb (%) 3 (11) 0 (0) 3 (8) 4 (9)
aNumber and percentage of subjects who carry one or more rare alleles according to previously dened four common alleles by Southern blotting analyses. Alleles with 30, 46, 69, or 87
repeats corresponding to common alleles a1, a2, a3, and a4, respectively; all else are rare alleles. 
bNumber and percentage of subjects who carry one or more rare alleles according to Conway’s (K.C.) denition: 33, 39, 42, 53, 59, 63, 68, 84, 105, and 114 repeats are rare; all else
are common.
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